Akili Management

Management criteria checks 1/4

Akili's CEO is Matt Franklin, appointed in Aug 2022, has a tenure of 1.92 years. total yearly compensation is $1.38M, comprised of 34.1% salary and 65.9% bonuses, including company stock and options. directly owns 0.96% of the company’s shares, worth $324.99K. The average tenure of the management team and the board of directors is 1.9 years and 1.9 years respectively.

Key information

Matt Franklin

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage	34.1%
CEO tenure	1.9yrs
CEO ownership	1.0%
Management average tenure	1.9yrs
Board average tenure	1.9yrs

Recent management updates

Recent updates

Akili surges 21% as Singapore investment firms take joint stake

Aug 26

CEO Compensation Analysis

How has Matt Franklin's remuneration changed compared to Akili's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$1m	US$472k	-US$59m
Sep 30 2023	n/a	n/a	-US$65m
Jun 30 2023	n/a	n/a	US$2m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$3m	US$239k	-US$19m

Compensation vs Market: Matt's total compensation ($USD1.38M) is above average for companies of similar size in the US market ($USD697.54K).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.

CEO

Matt Franklin (50 yo)

1.9yrs

Tenure

US$1,383,374

Compensation

Mr. Matthew Franklin, also known as Matt, M.B.A. is President at Akili Inc. from August 2022 and had been its Chief Operating Officer since August 2022 until October 5, 2023 and serves as its Chief Executi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Walter Martucci	Co-Founder & Chairman	1.9yrs	US$1.29m	0.052% $ 17.8k
Matthew Franklin	President	1.9yrs	US$1.38m	0.96% $ 325.0k
Adam Gazzaley	Co-Founder	no data	US$126.45k	1.38% $ 470.6k
Jacqueline Studer	Chief Legal Officer	1.9yrs	US$873.07k	0.039% $ 13.3k
Jonathan David	Chief Product Officer	1.9yrs	no data	no data

1.9yrs

Average Tenure

50yo

Average Age

Experienced Management: AKLI's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Walter Martucci	Co-Founder & Chairman	1.9yrs	US$1.29m	0.052% $ 17.8k
Matthew Franklin	President	less than a year	US$1.38m	0.96% $ 325.0k
Adam Gazzaley	Co-Founder	1.9yrs	US$126.45k	1.38% $ 470.6k
Christine Lemke	Independent Non-Executive Director	1.9yrs	US$74.25k	0% $ 0
John Spinale	Independent Director	less than a year	no data	0% $ 0
Mary Hentges	Independent Director	1.8yrs	US$86.75k	0% $ 0
William Jones	Independent Non-Executive Director	1.9yrs	US$77.88k	0% $ 0

1.9yrs

Average Tenure

54yo

Average Age

Experienced Board: AKLI's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Akili Management

Management criteria checks 1/4

Key information

Recent management updates

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board

Akili, Inc. Announces CEO Changes

Akili, Inc. Announces CEO Changes

Akili, Inc. Announces the Appointment of Scott Kollins, Ph.D., as Chief Medical Officer, Effective December 1, 2022

Recent updates

Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index

Akili to Delist from Nasdaq

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Akili, Inc. to Report Q1, 2024 Results on May 14, 2024

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product

Akili, Inc. Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan

New major risk - Share price stability

Akili, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board

Price target increased by 25% to US$5.00

Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Akili Receives Non-Compliance Notice from Nasdaq

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce

Akili, Inc. Announces CEO Changes

Akili, Inc. Announces CEO Changes

Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd

Price target decreased by 25% to US$3.00

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 14%

Consensus revenue estimates decrease by 44%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akili Releases EndeavorOTC Video Game Treatment to Improve Attention in Adults with Adad

Akili, Inc. to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with Adolescents At 2023

Consensus revenue estimates increase by 32%, EPS downgraded

Price target decreased by 8.3% to US$3.44

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 26%, EPS upgraded

Full year 2022 earnings released: US$0.10 loss per share (vs US$106 loss in FY 2021)

Akili, Inc. announces Pivotal Trial of Endeavorrx in Adolescents with Adhd Shows Robust Improvements in Attention and Broader Clinical Outcomes

Akili, Inc. Announces the Appointment of Scott Kollins, Ph.D., as Chief Medical Officer, Effective December 1, 2022

Consensus forecasts updated

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$35.91 (vs US$15.61 loss in 3Q 2021)

Akili, Inc. Announces Board Changes

Akili surges 21% as Singapore investment firms take joint stake

Second quarter 2022 earnings released

No independent directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age